Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 5/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24751979 | 1.00 | PIK3CD (0.33) | PIK3CDPDGFRAPIK3CAPIK3CBPIK3CG | |
| SCHEMBL24752005 | 0.80 | ADORA2A (0.33) | — | |
| SCHEMBL18215200 | 0.79 | ADORA2A (0.33) | — | |
| Hydrochloric Acid SCHEMBL18209731 | 0.77 | ADORA2A (0.32) | — | |
| SCHEMBL30067020 | 0.75 | MAPT (0.36) | — | |
| SCHEMBL30137872 | 0.75 | MAPT (0.36) | — | |
| SCHEMBL30067166 | 0.74 | JAK2 (0.33) | DHODH | |
| SCHEMBL24752314 | 0.74 | JAK2 (0.33) | DHODH | |
| SCHEMBL24752071 | 0.73 | DHODH (0.33) | PIK3CDPDGFRAPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30067142 | 0.73 | DHODH (0.33) | PIK3CDPDGFRAPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355748-B1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20240383901-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-11-21 | — | — | US | disclosed |
| EP-4355748-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022263472-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-12-22 | — | — | WO | disclosed |
| EP-4105218-A1 | SUBSTITUTED PYRROLO[2,3-D] PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383901-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | LRRK2, PARK7, SNCA | PIK3CD 511/4885PDGFRA 215/4885PIK3CA 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.